Active ingredientVandetanibCat. No. P-V016-001CAS 443913-73-3Family · Pharmaceutical analytical standards
Vandetanib
An oral inhibitor of several tyrosine kinases (VEGFR, EGFR and RET), approved in the United States in 2011 for advanced or metastatic medullary thyroid cancer. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It was the first medicine approved by the FDA for late-stage medullary thyroid cancer, a rare form accounting for about 3% of thyroid cancers.
Go to the active ingredient →Active ingredientVandetanibCat. No. P-V016-001CAS 443913-73-3
Isotopically labelledN-Demethyl Vandetanib-D4Cat. No. P-V016-002CAS 1346603-93-7
Isotopically labelledVandetanib-d4Cat. No. P-V016-003CAS 1215100-18-7
Isotopically labelledVandetanib-d6Cat. No. P-V016-004CAS 1174683-49-8
ImpurityN-Desmethyl VandetanibCat. No. P-V016-005CAS 338992-12-4
ImpurityO-Desmethyl VandetanibCat. No. P-V016-006CAS 910298-60-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.